FreeStyle Libre 2 (adults and children 4 years and older) FreeStyle Libre 3 (adults and children 4 years and older) Similar ...

With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...

The FreeStyle Libre by Abbott can provide prick-free on-demand sugar readings that offer detailed insights with just a scan ...

Abbott has announced that Tandem Diabetes Care’s t:slim X2 insulin pump has become the first automated insulin delivery (AID) system to integrate with its newly available FreeStyle Libre 2 Plus sensor ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

The planned launch of Omnipod 5 with Abbott’s Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock.

Worldwide Medical Devices sales increased 11.7% on a reported basis and 13.3% on an organic basis in the third quarter, ...

The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets.

DexCom markets one of the world's most popular constant blood glucose monitors (CGM). These discreet devices adhere to the ...